Trial · NCT00819741
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Glycosylated Haemoglobin A1c (HbA1c) | week -2 (screening), week 16 | Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product. | percentage (%) of total haemoglobin | LEAST_SQUARES_MEAN |
| SECONDARY | Change in Fasting Plasma Glucose | week 0, week 16 | Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product. | mmol/L | LEAST_SQUARES_MEAN |
| SECONDARY | Change in 2-hour Postprandial Plasma Glucose | Week 0, week 16 | Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product. | mmol/L | LEAST_SQUARES_MEAN |
| SECONDARY | Change in 7-point Plasma Glucose Profile | Week 0, week 16 | Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product. | mmol/L | LEAST_SQUARES_MEAN |
| SECONDARY | Change in Fasting Serum Insulin | Week 0, week 16 | Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product. A total of 100 subjects (50 per study group) out of the total subjects were randomly selected in the trial. Four trial sites were selected for the subgroup study. | mU/L | LEAST_SQUARES_MEAN |
| SECONDARY | Change in 2-hour Postprandial Serum Insulin | Week 0, week 16 | Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product. A total of 100 subjects (50 per study group) out of the total subjects were randomly selected in the trial. Four trial sites were selected for the subgroup study. | mU/L | LEAST_SQUARES_MEAN |
| SECONDARY | Change in Fasting Serum C-peptide | Week 0, week 16 | Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product. A total of 100 subjects (50 per study group) out of the total subjects were randomly selected in the trial. Four trial sites were selected for the subgroup study. | ng/ml | LEAST_SQUARES_MEAN |
| SECONDARY | Change in 2-hour Postprandial Serum C-peptide | Week 0, week 16 | Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product. A total of 100 subjects (50 per study group) out of the total subjects were randomly selected in the trial. Four trial sites were selected for the subgroup study. | ng/ml | LEAST_SQUARES_MEAN |
| SECONDARY | Hypoglycaemic Episodes | Weeks 0-16 | Safety analysis set was defined as all randomised and exposed subjects. | episodes | NUMBER |
| SECONDARY | Change in Blood Pressure | Week 0, week 16 | Safety analysis set was defined as all randomised and exposed subjects. | mmHg | MEAN |
| SECONDARY | Physical Examinations | Week -2, week 16 | Safety analysis set was defined as all randomised and exposed subjects. | Subjects | NUMBER |
| SECONDARY | ECG (ElectroCardioGram) | Week -2, week 16 | Safety analysis set was defined as all randomised and exposed subjects. | Subjects | NUMBER |
| SECONDARY | Biochemistry: Alanine Aminotransferase (ALAT) | Week -2, week 16 | Safety analysis set was defined as all randomised and exposed subjects. | Subjects | NUMBER |
| SECONDARY | Biochemistry: Alanine Aminotransferase (ASAT) | Week -2, week 16 | Safety analysis set was defined as all randomised and exposed subjects. | Subjects | NUMBER |
| SECONDARY | Haematology: Haemoglobin | Week -2, week 16 | Safety analysis set was defined as all randomised and exposed subjects. | Subjects | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00819741/outcomes